Haleon (NYSE:HLN) Stock Rating Lowered by Barclays

Barclays lowered shares of Haleon (NYSE:HLN) from an overweight rating to an equal weight rating in a report issued on Tuesday, MarketBeat reports.

Other analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Haleon from a “buy” rating to a “hold” rating in a research note on Saturday, July 12th. BNP Paribas Exane upgraded shares of Haleon from a “neutral” rating to an “outperform” rating and set a $13.40 price objective on the stock in a research note on Tuesday, May 27th. BNP Paribas upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, May 27th. Finally, The Goldman Sachs Group upgraded shares of Haleon from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 10th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Trading Down 1.5%

Shares of Haleon stock opened at $9.26 on Tuesday. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48. Haleon has a 12-month low of $8.86 and a 12-month high of $11.42. The firm has a market capitalization of $41.45 billion, a price-to-earnings ratio of 23.74, a PEG ratio of 2.77 and a beta of 0.24. The firm’s 50 day simple moving average is $9.67 and its two-hundred day simple moving average is $10.18.

Haleon Increases Dividend

The firm also recently declared a semi-annual dividend, which was paid on Thursday, September 18th. Stockholders of record on Friday, August 15th were paid a $0.0555 dividend. This is an increase from Haleon’s previous semi-annual dividend of $0.05. This represents a dividend yield of 190.0%. The ex-dividend date of this dividend was Friday, August 15th. Haleon’s payout ratio is 28.21%.

Hedge Funds Weigh In On Haleon

Several hedge funds and other institutional investors have recently modified their holdings of HLN. Brighton Jones LLC purchased a new position in shares of Haleon in the fourth quarter worth about $187,000. Ameriprise Financial Inc. lifted its stake in shares of Haleon by 15.8% in the fourth quarter. Ameriprise Financial Inc. now owns 120,122 shares of the company’s stock worth $1,146,000 after buying an additional 16,429 shares in the last quarter. Focus Partners Wealth lifted its stake in shares of Haleon by 132.0% in the fourth quarter. Focus Partners Wealth now owns 67,928 shares of the company’s stock worth $686,000 after buying an additional 38,651 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Haleon by 82.5% in the fourth quarter. Millennium Management LLC now owns 528,891 shares of the company’s stock worth $5,046,000 after buying an additional 239,019 shares in the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of Haleon by 62.6% in the fourth quarter. Royal Bank of Canada now owns 2,733,615 shares of the company’s stock worth $26,078,000 after buying an additional 1,052,462 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.